### **Title page**

Is mRankin scale correlated with mTICI? A systematic review and meta-regression on RCTs and registries.

# **Authors**

Gianluca De Rubeis MD<sup>1°</sup>, Enrico Pampana MD<sup>1°</sup>, Prof, Luca Prosperini MD<sup>2</sup>, Sebastiano Fabiano MD<sup>1</sup>, Luca Bertaccini MD<sup>1</sup>, Sabrina Anticoli MD<sup>3</sup>, Luca Saba MD, Prof<sup>4</sup>, Claudio Gasperini MD<sup>2</sup>, Prof, and Enrico Cotroneo MD<sup>1</sup>

°Co-first author, equally contribution to the manuscript

# **Affiliations**

1: Department of Diagnostic, UOC of Diagnostic and Interventional Neuroradiology, San Camillo-Forlanini Hospital, Rome, Italy

2: Department of Neuroscience, UOC Neurology, S Camillo Forlanini Hospital, Rome Italy

3: Emergency Department, UOSD Stroke Unit, S. Camillo-Forlanini Hospital, Rome, Italy

4: Department of Medical Imaging, Azienda Ospedaliero Universitaria (A.O.U.) of Cagliari-Polo di Monserrato, Cagliari, Italy

# **Keywords**

Stroke

Cerebral Infarction

Randomized Controlled Trial

**Observational Study** 

Mechanical Thrombolysis

### <u>Abstract</u>

## **Background and Purpose**

mTICI  $\geq$ 2b/3 is one of the strongest positive predictors of mRS  $\leq$ 2. Quantitative analysis is poorly investigated. Reconcile results from RCT and registries is still a challenge.

The purpose was to evaluate the numeric correlation between mTICI≥2b/3 and mRS≤2 in RCT and registries.

## Methods

Literature research was performed on Pubmed for studies in 2015-2020. mTICI, mRS and sample size were recorded. Exclusion criteria were monocentric study, not-human and not-English. Studies quality were assessed with MINORS and RoB2. Meta-logistic and meta-linear regressions were used to correlate mTICI and mRS in both RCTs and registries. Z-test was used for comparing coefficients between RCTs and registries.

## Results

Twenty-six studies were evaluated (13 registries; 14 RCTs) for 24423 patients (21914 from registries [average per registry 1685±1277]; 2509 from RCTs [average per RCT 179±160]). RCTs involved anterior circulation only, 7/13 (53.8%) registries considered also posterior one.

The OR of obtaining a mRS $\leq 2$  for a singular increased of mTICI $\geq 2b$  rate was 1.65 (CI95% 1.22-2.01) for all studies, 1.65 (CI95% 1.10-2.46) for RCTs and 1.50 (CI95% 1.00-2.23) for registries. mTICI $\geq 2b$  and mRS had a positive correlation with a coefficient of 0.49 (CI95% 0.19-0.80, p=0.001) for all studies, 0.54 (CI95% 0.09-1.00) for RCTs and 0.42 (CI 95% 0.04-0.81) for registries. No differences were found in the coefficients between RCTs and registries (p=0.63; p=0.65; respectively).

# **Conclusions**

Unitary increased of mTICI $\geq$ 2b rate correspond to an augment of mRS $\leq$ 2 by 0.50 (CI95% 0.19-0.89) with OR of obtaining mRS $\leq$ 2 of 1.65 (CI95% 1.22-2.01), without significantly differences in coefficients.

#### <u>Manuscript</u>

### Introduction

Since the publication in 2015 of the successful 5 randomized controlled trials (RCT)[1] on the endovascular mechanical thrombectomy, the new era of stroke treatment has begun. In the following years, a submergent literature has been published including RCTs and registries. mRankin scale (mRS) at 90 days is the functional primary endpoint in all RCTs and, generally, it is dichotomized into 0-2 (good functional outcome) and  $\geq 3[1 \ 2]$ . However, from procedural side, the goal is modified thrombolysis in cerebral infarction (mTICI) of  $\geq 2b[3]$  (successful revascularization). Although, a positive correlation between mTICI v and mRS $\leq 2$  is well established[4-6], a numerical analysis is poorly investigated.

RCTs is the gold standard for medical research, however registries could represented the "real-world" clinical practise[7]. A reconciliation between results originating from RCTs and registries is still a challenging in medicine[8]. Although, a Cochrane's systematic review[7] showed little differences in healthcare outcomes between these two types of study (rate of odds ratio: 1.08), Deb-Chatterji et al[9] demonstrated a worst performance for functional independency and mortality in stroke registry data comparing with the "first five" trials and HERMES meta-analysis data.

The aim of the present study was to evaluate the numerical correlation between successful recanalization (mTICI $\geq$ 2b/3) and good functional outcome (mRS $\leq$ 2) in both RCTs and registries using meta-regressions.

#### Methods

The study protocol was available upon request by mailing the corresponding author. The data used for the systematic review and the meta-regressions were publicly available.

Literature research in Pubmed was performed for published multicentric RCTs and registries, from 2015 (first publication of successful RCT in endovascular stroke) to 2020, on mechanical thrombectomy in stroke. The keywords were "stroke", "thrombectomy", "randomize controlled trial" and "registry". The inclusion criteria for the studies were: English literature, humans, and mechanical thrombectomy in at least one of the study's arm. Title and abstract were reviewed for considering inclusion. Further the full text was analysed. Monocentric studies were excluded. For ASTER[10] and COMPASS[11] trials, which compared contact aspiration and stent retriever, the data were considered unitary. For DIRECT-MT trial[12] which confronted

endovascular treatment with or without Alteplase administration, the data were considering unified. The detailed flowchart was described in **Figure 1**.

#### Study quality assessment

Studies quality was assessed with methodological index for non-randomized studies (MINORS) criteria[13] for registry and with Risk of Bias 2 (RoB2) tool[14] for RCT. The results of the assessment were described in **Table 1**.

#### Data extraction, statistical analysis, and results interpretation

For each study, the percentage of successful revascularization (mTICI $\geq$ 2b), rate of good functional outcome at 90 days (mRS $\leq$ 2) and the number of patients enrolled were recorded (Table 1.). Data were divided into two categories: RCT and registry. The data extraction were performed by two interventional neuroradiologist in consensus (BLIND and BLIND, 4 and 5 years of experiences, respectively).

The data were analysed using meta logistic regression analysis with random effect model, using as covariate: mTICI $\geq$ 2b, studies involved also posterior circulation and types of studies (RCTs and registries). Since, the mRS percentage across the studies are continuous data and follow a normal distribution (Kolmogorov-Smirnov test), these data respect also the assumption of central limit theorem to perform a meta linear regression analysis[15]. Both linear and logistic meta-regressions were performed. Z's test proposed by Clogg et al[16] was used for comparing the coefficient of the two meta-regressions. p $\leq$ 0.05 was considered as significant. R-Studio (R-project http://www.R-project.org) and OpenMeta version 12.11.14 (http://www.cebm.brown.edu/openmeta/index.html) were used as statistical software. The graphs were plotted with Microsoft Excel (Office 365, Microsoft Corporation, Redmond, USA).

Meta-regression was performed using both linear and logistic setting (according to the central limit theorem) due the different interpretation of the data resulted by the analysis. In particular, the coefficient of meta linear regression described the numerical correlation between mTICI percentage and 3-months mRS rate, more specifically the coefficient corresponds to how much the percentage of mRS $\leq$ 2 increases per single increase in mTICI $\geq$ 2b rate. On the contrary the odd ratio, derived from the meta logistic regression, represents the constant effect of a mTICI $\geq$ 2b percentage, on the likelihood that mRS $\leq$ 2 rate will occur; in the other words, the augmented chances of obtaining mRS $\leq$ 2 per single increase of mTICI $\geq$ 2b percentage.

### Study's Outcomes

The primary outcome was to evaluate the correlation and the numeric relationship between successful revascularization (mTICI $\geq$ 2b) and good functional outcome at 90 days (mRS $\leq$ 2).

The secondary outcome was to observe if the correlation and the numeric relationship varied between RCTs and registries.

#### <u>Results</u>

#### Study population

The final population encompassed 27 studies (14 registries and 13 RCTs) for a total number of patients of 24423 divided into 21914 from registries (average per registry  $1685\pm1277$ ) and 2509 from RCTs (average per RCT 179±160) (**Flowchart 1.**). All RCTs were focused only anterior circulation while 7/13 (53.8%) of the registries considered also posterior one. (**Table 1**). A detailed list of inclusion criteria of the studies were described in **Table 1**.

### Results

The heterogeneity of the studies was high with an  $I^2=92.8\%$ , which decreased to  $I^2=75.9\%$  considering RCTs only and increased to I2=95.7% for registries.

The coefficient of the meta-logistic regression analysis for mTICI  $\geq$ 2b was 0.50 (CI95% 0.20-0.70. p=0.001) for all studies, with a corresponding Odd-Ratio (OR) of 1.65 (CI95% 1.22-2.01) (**Figure 2**); no other covariates were significant (**Table 2**). By performing meta logistic regression using mTICI and trial type as covariates, the coefficient for registries was -4.00 (CI95% -9.0-1.0, p=0.12) with an OR 0.018 (CI95% 0.0001-0.37). For RCTs, the coefficient was 0.50 (CI95% 0.10-0.90. p=0.02) with an OR of 1.65 (CI95% 1.10-2.46) and for registries was 0.40 (CI 95% 0.0-0.80 p=0.03) with an OR of 1.5 (CI95% 1.00-2.23). No differences were highlighted between the two coefficients (z=0.35; p=0.63)

The coefficient of the meta-linear regression analysis for mTICI $\geq$ 2b was 0.49 (CI95% 0.19-0.80, p=0.001) (**Figure 2**), by means that on average an increase of 1% of mTICI $\geq$ 2b will increase the chance of obtaining a good functional outcome (mRS  $\leq$ 2) by 0.49%; no other covariates were significant (**Table 3**.). After performing the meta linear regression using as covariates mTICI and trial type only, the coefficient for registries was -4.54 (CI95% -9.89-0.80, p=0.10). For RCTs, the coefficient was 0.54 (CI95% 0.09-1.00, p=0.02) and for registries was 0.42 (CI 95% 0.04-0.81, p=0.03). No differences were demonstrated between the two coefficients (z=0.39; p=0.65)

### Discussion

The OR of obtaining a functional independency (mRS $\leq$ 2) for a unitary increased of mTICI  $\geq$ 2b was 1.65 (CI95% 1.22-2.01) for all studies and 1.65 (CI95% 1.10-2.46) for RCTs and 1.5 (CI95% 1.00-2.23) for registries. A linear positive correlation was found between mTICI $\geq$ 2b and mRS with a coefficient of 0.49 (CI95% 0.19-0.80, p=0.001) for all studies, 0.54 (CI95% 0.09-1.00) for the RCTs and 0.42 (CI 95% 0.04-0.81, p=0.03) for registries, without significant differences between the two coefficients (p>0.05).

Successful revascularization (mTICI $\geq$ 2b) is considered one of the strongest predictor of functional independency (mRS $\leq$ 2)[6], for this reason the AHA/ASA guidelines[3] addressed mTICI $\geq$ 2b as the angiographic goal for maximizing the chance of obtaining good functional clinical outcome. A linear relationship between mTICI and mRS in RCTs was already observed; although, without numeric analysis[17 18]. The present meta-linear regression numerically confirmed the significantly correlation defining a comprehensive coefficient of 0.49 (CI95% 0.19-0.80, p=0.001). In addition, applying the meta-logistic regression the OR of obtain functional independency was 1.65 (CI95% 1.22-2.01).

Despite, RCTs is considered the gold standard for medical research, the problem of transporting results to "real-life world" is still an unsolved problem in medicine[19]. Basically, the internal validity of RCT may limit its external validity due to the different conditions and homogeneity of a RCT compared to the more complex and heterogeneous setting of a registry [20] 21]. Moreover, performance bias is a matter of concern in both RCTs and registries, especially for non-pragmatic RCT in which the issues of "structured environment" may limited results generalization[22-24]. In addition, RCTs' patients are generally strictly monitored and more sensitized on the disease comparing with observational registries [25]. In addition, mRS has several limitations including long time span between treatment and outcome assessment and lack of strokespecificity disability[26]. In addition, mRS is influenced also by post-stroke care and rehabilitation[27-30]. The present data regarding mechanical thrombectomy in stroke partially confirmed these results. In fact, both the OR (meta-logistic regression) and the coefficient (metalinear regression) were higher in RCT vs registries (OR: 1.65 [CI95% 1.10-2.46] vs 1.5 [CI95% 1.00-2.23], respectively) (coefficient: 0.54 [CI95% 0.09-1.00] vs 0.42 [CI 95% 0.04-0.81], respectively) (Figure 2.). These findings meaned that by increasing of 1% in mTICI≥2b rate the corresponding chance of augment of mRS  $\leq 2$  was 0.54 for RCTs and 0.42 registries. Namely, an angiographic success in mechanical thrombectomy has a higher impact on the clinical functional outcome if the patient is enrolled in a RCT despite in a registry. Despite its clinical importance,

these differences remained not statistically significant in this present study due to small sample size. Interestingly, the lowest performance of mRS $\leq 2$  was reported by MR-CLEAN trial[31], the sole RCT who explicitly affirmed its pragmatic design. Under these lights, a direct comparison of a 3 months functional scale between real world (registries) and experimental setting (RCTs) is difficult to establish.

These discrepancies in clinical outcome may arise from several points. Firstly, RCTs and registries design (structured vs real world). Secondly, RCTs' centres may be more expert in mechanical thrombectomy than registries' one with a higher number of procedures per year which is a known prognostic factor[32]. Thirdly, the post-stroke care could be more effective in a high-volume centre. Fourthly, since a double-blind design is unfeasible, an assignment bias may impact on the results.

The current study presents several limitations. Firstly, the literature research was performed on PubMed and the authors did not have the access to original data. Secondly, the post-stroke care quality was not possible to assess, since was not reported in any papers. Thirdly, the studies presented different inclusion criteria which may slightly influence the enrolment. Fourthly, the ecological bias is a known and intrinsic limitation of meta regression analysis[33], since average patient characteristics are regressed against average trial outcomes and the data were extracted not at patients level[34]

### **Conclusions**

For each unitary increased of mTICI $\geq$ 2b rate, the percentage of mRS<2 augment by 0.49 (CI95% 0.19-0.80) and the OR of obtaining a good functional outcome was 1.65 (CI95% 1.10-2.26), without significant differences between RCTs and registries performance.

# Contributorship Statement:

Conceptualization, GDR and EP; methodology, GDR, LP and CG; software, GDR and LP.; validation CG, EP, SF, SA and EC.; formal analysis, GDR and LP; investigation GDR, LB, SF, EP; resources LB; data curation, GDR, LB and LP.; writing—original draft preparation, GDR, EP; writing—review and editing CG; SA and EC.; visualization GDR, LP.; supervision, EP, CG, SF, SA EC;

# **Funding Statement:**

This research received no specific grant from any funding agency in the public, commercial or notfor-profit sectors.

# **Competing Interests Statement:**

NA

All authors have read and agreed to the published version of the manuscript.

# **Ethical approval:**

Not applicable, since this is a meta-regressions based on literature research

# Data sharing:

Data are available upon request to the corresponding author

## **References**

- Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016;387(10029):1723-31 doi: 10.1016/s0140-6736(16)00163-x[published Online First: Epub Date]|.
- Broderick JP, Adeoye O, Elm J. Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. Stroke 2017;48(7):2007-12 doi: 10.1161/STROKEAHA.117.017866[published Online First: Epub Date]|.
- 3. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019;50(12):e344-e418 doi: 10.1161/STR.00000000000211[published Online First: Epub Date]|.
- 4. Kaesmacher J, Dobrocky T, Heldner MR, et al. Systematic review and meta-analysis on outcome differences among patients with TICI2b versus TICI3 reperfusions: success revisited. Journal of Neurology, Neurosurgery & amp; amp; Psychiatry 2018;89(9):910 doi: 10.1136/jnnp-2017-317602[published Online First: Epub Date]|.
- 5. Dargazanli C, Fahed R, Blanc R, et al. Modified Thrombolysis in Cerebral Infarction 2C/Thrombolysis in Cerebral Infarction 3 Reperfusion Should Be the Aim of Mechanical Thrombectomy: Insights From the ASTER Trial (Contact Aspiration Versus Stent Retriever for Successful Revascularization). Stroke 2018;49(5):1189-96 doi: 10.1161/strokeaha.118.020700[published Online First: Epub Date]|.
- 6. Pego-Perez ER, Fernandez-Rodriguez I, Pumar-Cebreiro JM. National Institutes of Health Stroke Scale, modified Rankin Scale, and modified Thrombolysis in Cerebral Infarction as autonomy predictive tools for stroke patients. Reviews in the neurosciences 2019 doi: 10.1515/revneuro-2019-0011[published Online First: Epub Date]|.
- 7. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database of Systematic Reviews 2014(4) doi: 10.1002/14651858.MR000034.pub2[published Online First: Epub Date]|.
- 8. Ross JS. Randomized Clinical Trials and Observational Studies Are More Often Alike Than Unlike. JAMA Internal Medicine 2014;**174**(10):1557-57 doi: 10.1001/jamainternmed.2014.3366[published Online First: Epub Date]|.
- 9. Deb-Chatterji M, Pinnschmidt H, Flottmann F, et al. Stroke patients treated by thrombectomy in real life differ from cohorts of the clinical trials: a prospective observational study. BMC neurology 2020;20(1):81 doi: 10.1186/s12883-020-01653-z[published Online First: Epub Date].
- Ducroux C, Piotin M, Gory B, et al. First pass effect with contact aspiration and stent retrievers in the Aspiration versus Stent Retriever (ASTER) trial. 2020;12(4):386-91 doi: 10.1136/neurintsurg-2019-015215[published Online First: Epub Date]|.
- 11. Turk AS, 3rd, Siddiqui A, Fifi JT, et al. Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial. Lancet 2019;**393**(10175):998-1008 doi: 10.1016/s0140-6736(19)30297-1[published Online First: Epub Date]|.
- 12. Yang P, Zhang Y, Zhang L, et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke. New England Journal of Medicine 2020;**382**(21):1981-93 doi: 10.1056/NEJMoa2001123[published Online First: Epub Date]].
- 13. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ journal of surgery 2003;73(9):712-6 doi: 10.1046/j.1445-2197.2003.02748.x[published Online First: Epub Date]|.
- 14. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 2019;**366**:14898 doi: 10.1136/bmj.14898[published Online First: Epub Date]|.

- Jackson D, White IR. When should meta-analysis avoid making hidden normality assumptions? Biometrical journal Biometrische Zeitschrift 2018;60(6):1040-58 doi: 10.1002/bimj.201800071[published Online First: Epub Date]|.
- 16. Clogg CC, Petkova E, Haritou A. Statistical methods for comparing regression coefficients between models. American journal of sociology 1995;**100**(5):1261-93
- Manning NW, Chapot R, Meyers PM. Endovascular Stroke Management: Key Elements of Success. Cerebrovascular diseases 2016;42(3-4):170-7 doi: 10.1159/000445449[published Online First: Epub Date]|.
- 18. Andersson T, Wiesmann M, Nikoubashman O, et al. The Aspirations of Direct Aspiration for Thrombectomy in Ischemic Stroke: A Critical Analysis. J Stroke 2019;**21**(1):2-9 doi: 10.5853/jos.2018.02026[published Online First: Epub Date]|.
- 19. Frieden TR. Evidence for Health Decision Making Beyond Randomized, Controlled Trials. The New England journal of medicine 2017;**377**(5):465-75 doi: 10.1056/NEJMra1614394[published Online First: Epub Date]|.
- 20. Spieth PM, Kubasch AS, Penzlin AI, et al. Randomized controlled trials a matter of design. Neuropsychiatric disease and treatment 2016;12:1341-9 doi: 10.2147/NDT.S101938[published Online First: Epub Date]|.
- 21. Faraoni D, Schaefer ST. Randomized controlled trials vs. observational studies: why not just live together? 2016;16(1):102
- 22. Mansournia MA, Higgins JP, Sterne JA, et al. Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists. Epidemiology 2017;**28**(1):54-59 doi: 10.1097/EDE.00000000000564[published Online First: Epub Date]].
- 23. Schnell-Inderst P, Iglesias CP, Arvandi M, et al. A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement. Health Economics 2017;**26**(S1):46-69 doi: https://doi.org/10.1002/hec.3474[published Online First: Epub Date]|.
- 24. Gamerman V, Cai T, Elsäßer A. Pragmatic randomized clinical trials: best practices and statistical guidance. Health Services and Outcomes Research Methodology 2019;**19**(1):23-35 doi: 10.1007/s10742-018-0192-5[published Online First: Epub Date]|.
- Saturni S, Bellini F, Braido F, et al. Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulmonary Pharmacology & Therapeutics 2014;27(2):129-38 doi: https://doi.org/10.1016/j.pupt.2014.01.005[published Online First: Epub Date]|.
- 26. Chalos V, van der Ende NAM, Lingsma HF, et al. National Institutes of Health Stroke Scale: An Alternative Primary Outcome Measure for Trials of Acute Treatment for Ischemic Stroke. Stroke 2020;**51**(1):282-90 doi: 10.1161/STROKEAHA.119.026791[published Online First: Epub Date]].
- 27. Huang H-C, Tsai J-Y, Liu T-C, et al. Functional recovery of stroke patients with postacute care: a retrospective study in a northern medical center. Journal of the Chinese Medical Association 2019;82(5)
- 28. Deutsch A. Does Postacute Care Site Matter? A Longitudinal Study Assessing Functional Recovery After a Stroke. Archives of Physical Medicine and Rehabilitation 2013;94(4):630-32 doi: https://doi.org/10.1016/j.apmr.2013.02.011[published Online First: Epub Date]|.
- 29. Middleton S, McElduff P, Ward J, et al. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. The Lancet 2011;**378**(9804):1699-706
- 30. Cramer SC, Wolf SL, Adams Jr HP, et al. Stroke recovery and rehabilitation research: issues, opportunities, and the National Institutes of Health StrokeNet. Stroke 2017;**48**(3):813-19
- 31. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. The New England journal of medicine 2015;372(1):11-20 doi: 10.1056/NEJMoa1411587[published Online First: Epub Date]
- 32. Nogueira RG, Haussen DC, Castonguay A, et al. Site Experience and Outcomes in the Trevo Acute Ischemic Stroke (TRACK) Multicenter Registry. Stroke 2019;**50**(9):2455-60 doi: 10.1161/STROKEAHA.118.024639[published Online First: Epub Date]].

- 33. Baker WL, White CM, Cappelleri JC, et al. Understanding heterogeneity in meta-analysis: the role of meta-regression. International journal of clinical practice 2009;63(10):1426-34 doi: 10.1111/j.1742-1241.2009.02168.x[published Online First: Epub Date]|.
- 34. Berlin JA, Santanna J, Schmid CH, et al. Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Statistics in medicine 2002;**21**(3):371-87

# **Figures' legend**

## Figure 1.

Study flowchart

# Figure 2.

Bubble plot of the meta regression in RCTs (a) registries (b). As observed, the was a linear correlation between mTICI≥2b and mRS>2 using both analyses with a trending minor slope in registries. The size of the bubble represented the numerosity of the study

# **Tables**

Name	Туре	Trial type	Ye ar	Ris k of Bi as	Num ber of patie nts	Comparison for RCT Non-comparison for Registry	Inclusi on criteria	mTICI ≥2b (%)	90 days mRS ≤2 (%)
EXTEN D-IA <sup>a</sup>	RCT	Prospecti ve. blind end-point evaluatio n	201 5	Lo w	35	SR + Alteplase vs Alteplase alone	Alteplas e within 4.5 hours from the onset; Anterio r circulati on	86	71
REVAS CAT	RCT	Prospecti ve. sequentia l. blind end-point evaluatio n	201 5	Lo w	103	SR vs medical therapy	Treated within 8 hours from the onset; Anterio r circulati on	65.7	44
MR CLEAN	RCT	Prospecti ve. pragmati c. blind end-point evaluatio n	201 5	Lo w	233	SR or Thrombolytic Agent vs medical therapy	Treated within 6 hours from the onset; Anterio r circulati on	58.7	33
ESCAPE	RCT	Prospecti ve. blind end-point evaluatio n	201 5	Lo w	165	SR vs medical therapy	Treated within 12 hours from the onset; Anterio r circulati on	72.4	53
SWIFT- PRIME	RCT	Prospecti ve. blind	201 5	Lo w	98	SR + Alteplase vs Alteplase alone	Treated within 6	88	60

		and noint					hours		
		end-point evaluatio n					nours from the onset; Anterio r circulati on		
Therapy	RCT	Prospecti ve	201 6	Lo w	55	CA vs medical therapy	Eligible for alteplas e; Anterio r circulati on; NIHSS ≥8	70	38
THRAC E	RCT	Prospecti ve. blind end-point evaluatio n	201 6	Lo w	204	Mechanical trombectomy + alteplase vs alteplase	Treated within 5 hours from the onset; Anterio r circulati on	69	53
ASTER	RCT	Prospecti ve. blind end-point evaluatio n	201 7	Lo w	381	CA vs SR	Treated within 6 hours from the onset; Anterio r circulati on	84.8	47.6
PISTE <sup>a</sup>	RCT	Prospecti ve. blind end-point evaluatio n	201 7	Lo w	33	Mechanical thrombectomy + alteplase vs alteplase	Eligible for alteplas e; Anterio r circulati on;	87.4	51
STRATI S	Regis try	Prospecti ve	201 7	13	989	SR (Solitare)	Treated within 8 hours from the	87.9	56.5

							onset; Anterio r and Posterio r circulati		
SITS- TBY	Regis try	Prospecti ve	201 7	12	1053	Mechanical thrombectomy	on Europea n guidelin es; Anterio r circulati ons	74	48
ACTUA L	Regis try	Retrospe ctive	201 8	11	698	Mechanical thrombectomy	AHA/A SA indicati ons; Anterio r circulati on	83.8	43.8
<b>Trevo</b> 2000	Regis try	Prospecti ve	201 8	14	1192	SR (TREVO)	Center- based indicati ons	92.8	55.3
MR CLEAN	Regis try	Prospetiv e	201 8	11	1628	Mechanical thrombectomy	Treated within 6.5 hours from the onset; Anterio r circulati on	58.7	37.9
DEFUSE 3	RCT	Prospecti ve. blind end-point evaluatio n	201 8	Lo w	92	Mechanical thrombectomy	6-16 hours from the onset; imaging mismat ch; anterior circulati on	76	45
ETIS	Regis try	Prospecti ve	201 9	13	1541	Mechanical thrombectomy	AHA/A SA	76.6	44.1

							indicati		
							Anterio r and posterio r circulati ons		
COMPA SS	RCT	Prospecti ve. blind end-point evaluatio n	201 9	Lo w	270	CA vs SR	Treated within 6.5 hours from the onset; Anterio r circulati on	80.7	50.4
Track	Regis try	Retrospe ctive and prospecti ve	201 9	13	624	SR (TREVO)	AHA/A SA indicati ons; Anterio r and posterio r circulati ons	80.7	48.3
BEYON D- SWIFT	Regis try	Retrospe ctive	201 9	11	2046	Mechanical thrombectomy	AHA/A SA indicati ons; Anterio r and posterio r circulati ons	71.4	45.5
German	Regis try	Prospecti ve	201 9	13	2794	Mechanical thrombectomy	AHA/A SA indicati ons; Anterio r and posterio r circulati ons	83	37
Moscow	Regis try	Retrospe ctive	201 9	12	742	Mechanical thrombectomy	AHA/A SA	75	29.9

							indicati		
							ons; Anterio r and posterio r circulati ons		
STAR	Regis try	Unknown	202 0	12	3850	Mechanical thrombectomy	AHA/A SA indicati ons; Anterio r and posterio r circulati ons	84	41
IRETAS	Regis try	Retrospe ctive	202 0	13	4429	Mechanical thrombectomy	AHA/A SA indicati ons; Anterio r and posterio r circulati ons	75.1	43.7
Resiliet <sup>a</sup>	RCT	Prospecti ve	202 0	Lo w	111	Mechanical thrombectomy vs standard care	AHA/A SA indicati ons; Anterio r circulati on	82	35.1
TREAT	Regis try	Prospecti ve	202 0	11	328	Mechanical thrombectomy	AHA/A SA indicati ons; Anterio r and posterio r circulati ons	83.3	43.9
DIRECT MT	RCT	Proespect ive	202 0	Lo w	622	Mechanical thrombectomy vs Mechanical thrombectomy+A Iteplase	AHA/A SA indicati ons; Anterio	82.0	47.3

		r	
		circulati	
		on	

SR: stent retriever; CA: contact aspiration;  $\times$  Contact aspiration;  $^{\circ}$ Stent retriever;  $\alpha$  interrupted early; NIHSS: National Institute Health Stroke Scale

# Table 1. List of the studies

	Coefficient (n [CI95%])	р	Omnibus p
mTICI	0.50 [0.20-	0.001	0.006
	0.70]		
Posterior	-1.9 [-10.9-	0.685	0.006
circulation	7.20]		
Registry	-2.5 [-10.1-	0.515	0.006
	5.1]		

mTICI modified thrombolysis in cerebral infarction, CI 95% confidence interval 95%

Table 2. Meta logistic regression

	Coefficient (n [CI95%])	р	Omnibus p
mTICI	0.49 [0.19-	0.002	0.006
	0.80]		
Posterior	-1.89 [-11.11-	0.69	0.006
circulation	7.33]		
Registry	-3.34 [-12.31-	0.47	0.006
	5.64]		

mTICI modified thrombolysis in cerebral infarction, CI 95% confidence interval 95%

Table 3. Meta linear regression





RCTs

Registries